Frailty and muscle loss may predict outcomes in lung scarring patients

NCT ID NCT07004595

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 100 adults aged 65 and older with fibrosing interstitial lung disease, a condition that scars the lungs and shortens life. Researchers will assess frailty and muscle loss (sarcopenia) using questionnaires and tests to see if these factors predict hospital stays, disease worsening, or death. The goal is to help doctors tailor care for those most at risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors identify which patients need extra support or different treatments based on frailty and muscle loss.

What could go wrong

This is an observational study with only 100 participants, so results may not apply to everyone. It does not test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty pulmonary fibrosis Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU Nantes - Respiratory Department

    RECRUITING

    Nantes, Nantes, 44000, France

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••